Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: A striking contrast with vasopressin agonists

Journal of Peptide Science

Volumn 3, Issue 1, 1997, Pages 31-46

  Manning, Maurice ^a   Cheng, Ling Ling ^a   Stoev, Stoytcho ^a   Klis, Wieslaw A ^a,d   Nawrocka, Eleonora ^a   Olma, Aleksandra ^a   Sawyer, Wilbur H ^b   Wo, Nga Ching ^c   Chan, W Y ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b Columbia University ^*  (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF TOLEDO   (United States)

Author keywords

Aic; Antagonist; Atc; Oic; Receptor; Tic; Vasopressin

Indexed keywords

AMINO ACID; ARGIPRESSIN; ARGIPRESSIN,(1 MERCAPTOCYCLOHEXANEACETIC ACID)(1) O ETHYL TYR(2); ARGIPRESSIN,(1-MERCAPTOCYCLOHEXANEACETIC ACID)(1)-O-ETHYL-TYR(2)-; DRUG DERIVATIVE; LIGAND; PEPTIDE; RADIOACTIVE IODINE; VASOPRESSIN RECEPTOR;

ANIMAL; ARTICLE; BIOASSAY; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG POTENTIATION; ORAL DRUG ADMINISTRATION; PROTEIN CONFORMATION; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; AMINO ACIDS; ANIMALS; ARGININE VASOPRESSIN; BIOLOGICAL ASSAY; DRUG DESIGN; IODINE RADIOISOTOPES; LIGANDS; PEPTIDES; PROTEIN CONFORMATION; RATS; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030625001     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1387(199701)3:1<31::AID-PSC82>3.0.CO;2-Y     Document Type: Article

References (77)

1. M. Manning, L. L. Cheng, W. A. Klis, S. Stoev, J. Przybylski, K. Bankowski, W. H. Sawyer, C. Barberis and W. Y. Chan in: Oxytocin: Cellular and Molecular Approaches in Medicine and Research, R. Ivell and J. Russel, Eds., p. 557-583 Plenum Press, New York (1995).
2. M. Manning, L. L. Cheng, S. Stoev, W. H. Sawyer, E. Tribollet, C. Barberis, N. C. Wo and W. Y. Chan in: Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research, T. Saito, K. Kurokawa and S. Yoshido, Eds., p. 21-38, Elsevier, Amsterdam 1995.
3. P. A. Phillips, L. M. Burrell, C. B. Gow, C. I. Johnston, S. Grant, J. Risvanis and K. Aldred in Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research, T. Saito, K. Kurokawa and S. Yoshido, Eds., p. 643-658, Elsevier, Amsterdam 1995.
4. M. Manning, S. Stoev, W. Y. Chan and W. H. Sawyer (1993). Receptor-specific antagonists of vasopressin and oxytocin. A current perspective. Ann. NY Acad. Sci. 689, 219-232.
5. F. A. Lāszlo, F. Lāszlo Jr and D. De Wied (1991). Pharmacology and clinical perspectives of Vasopressin antagonists. Pharmacol. Rev. 43, 73-108.
6. W. H. Sawyer and M. Manning (1988). Experimental uses of neurohypophyseal hormone analogs. Trends Endocrinol. Metab. 1, 48-50.
7. M. Manning and W. H. Sawyer (1989). Discovery, development and some uses of vasopressin and oxytocin antagonists. J. Lab. Clin. Med. 114, 617-632.
8. L. B. Kinter, W. F. Huffman and F. L. Stassen (1988). Antagonists of the antidiuretic activity of vasopressin. Am. J. Physiol. 254, F165-F177.
9. V. J. Hruby and C. W. Smith in: The Peptides, S. Udenfriend and J. Meienhofer, Eds., p. 77-207, Orlando, FL, Academic Press 1987.
10. M. Lebl in: Handbook of Neurohypophysial Hormone Analogs, K. Jost, M. Lebl and F. Brtnik, Eds., p. 17-74, CRC Press, Boca Raton, FL 1987.
11. W. H. Sawyer, P. K. T. Pang, J. Seto, M. McEnroe, B. Lammek and M. Manning (1981). Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone. Science 212, 49-51.
12. M. Manning, A. Olma, W. A. Klis, A. M. Kolodzlejczyk, E. Nawrocka, A. Misicka-Kesik, J. Seto and W. H. Sawyer (1984). Carboxy terminus of vasopressin required for activity but not binding. Nature 308, 652-653.
13. M. L. Moore, W. F. Huffman, G. D. Roberts, S. Rottschaefer, L. Sulat, J. S. Stefankiewicz and F. Stassen (1984). Synthesis and characterization of iodinated vasopressin antagonists which retain high affinity to the vasopressin receptor. Biochem. Biophys. Res. Comm. 121, 878-883.
14. M. L. Moore, H. Greene, W. F. Huffman, F. Stassen, J. Stefankiewicz, L. Sulat, G. Heckman, D. Schmidt, L. Kinter, J. McDonald and D. Ashton-Shue (1986). Vasopressin antagonist analogs modified at position 7. Int. J. Peptide Protein Res. 28, 379-385.
15. M. Manning, J. Przybylski, A. Olma, W. A. Klis, M. Kruszynski, N. C. Wo, G. H. Pelton and W. H. Sawyer (1987). Cyclic conformation is not required for binding of antagonists to vasopressin receptors. Nature 329, 839-840.
16. 1-receptor) response to arginine-vasopressin. J. Med. Chem. 35, 382-388.
17. 1a receptors. FEBS Lett. 282, 77-81.
18. 1a vasopressin receptor. Eur. J. Biochem. 213, 711-719.
19. E. Carnazzi, A. Aumelas, C. Barberis, G. Guillon and R. Seyer (1994). A new series of photoactivatable and iodinatable linear vasopressin antagonists. J. Med. Chem. 37, 1841-1849.
20. 1a receptors. Neuroendocrinology 62, 135-146.
21. 1 receptor antagonist. Science 252, 571-572.
22. 2 receptor antagonist. Br. J. Pharmacol. 105, 787-791.
23. 1a receptors. J. Clin. Invest. 92, 224-231.
24. V. du Vigneaud, D. T. Gish and P. G. Katsoyannis (1954). A synthetic preparation possessing biological properties associated with arginine-vasopressin. J. Am. Chem. Soc. 76, 4751-5752.
25. P. G. Katsoyannis and V. du Vigneaud (1958). Arginine-vasotocin, a synthetic analogue of the posterior pituitary hormones containing the ring of oxytocin and the side chain of vasopressin. J. Biol. Chem. 233, 1352-1354.
26. C. W. Smith, M. F. Ferger and W. Y. Chan (1975). Synthesis and some pharmacological properties of [3-β-(2-Thienyl)-L-alanine]-8-lysine-vasopressin, J. Med. Chem. 18, 822-825.
27. B. Berde and R. A. Boissonnas in: Neurohypophysial Hormones and Similar Polypeptides. Handbook of Experimental Pharmacology Vol. 23, B. Berde, Ed., p. 802-870, Springer Verlag, Berlin 1968.
28. M. Lebl, K. Jost and F. Brtnik in: Handbook of Neurohypophyseal Hormone Analogs Vol. II, Part 2, K. Jost, M. Lebl and M. Brtnik, Eds., p. 127-267, CRC Press, Boca Raton, FL 1987.
29. A. Buku, I. L. Schwartz, D. Gazis, C. L. Ma and P. Eggena (1985). Synthesis and biological activities of a fluorescent photoaffinity analog of vasopressin. Endocrinology 117, 196-200.
30. Z. Prochazka, J. E. Anacanas, J. Slaninova, A. Machova, T. Barth and M. Lebl (1990). Synthesis and biological properties of vasopressin analogues containing 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid. Collect. Czech. Chem. Commun. 55, 1099-1105.
31. M. Manning, L. L. Cheng, S. Stoev, K. Bankowski, J. Przybylski, W. A. Klis, W. H. Sawyer, N. C. Wo and W. Y. Chan (1995). An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin. J. Peptide Sci. 1, 66-79.
32. M. Manning, A. Olma, W. A. Klis, A. Kolodziejczyk, J. Seto and W. H. Sawyer (1982). Design of more potent antagonists of the antidiuretic response to arginine-vasopressin. J. Med. Chem. 25, 45-50.
33. A. Pictet and T. Spengler (1911). The formation of isoquinoline derivatives through reaction of formaldehyde with phenethylamine, phenylalanine and tyrosine. Chem. Ber. 44, 2030-2036.
34. V. J. Hruby, F. Al-Obeidi and W. Kazimierski (1990). Emerging approaches in the molecular design of receptor-selective peptide ligands: Conformational, topographical and dynamic considerations. Biochem. J. 268, 249-262.
35. M. Manning, M. Kruszynski, K. Bankowski, A. Olma, B. Lammek, L. L. Cheng, W. A. Klis, J. Seto, J. Haldar and W. H. Sawyer (1989). Solid phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin. J. Med. Chem. 32, 382-391.
36. M. Manning, W. A. Klis, A. Olma, J. Seto and W. H. Sawyer (1982). Design of more potent and selective antagonists of the antidiuretic responses to arginine-vasopressin devoid of antidiuretic agonism. J. Med. Chem. 25, 414-419.
37. G. R. Marshall and H. E. Bosshard (1972). Angiotensin II: Studies on the biologically active conformation. Circ. Res. Suppl. II, 30-31: II, 143-150.
38. G. R. Marshall and H. E. Bosshard (1972). Angiotensin II: Studies on the biologically active conformation. Circ. Res. Suppl. II, 30-31: II, 143-150.
39. D. K. Chalmers and G. R. Marshall (1995). Pro-D-N-Me-amino acid and D-Pro-Nβ-Me-amino acid: Simple, efficient reverse turn constraints. J. Am. Chem. Soc. 117, 5927-5937.
40. F. J. Hock, K. Wirth, U. Albus, W. Linz, H. J. Gerhards, G. Wiemer, St. Henke, G. Breipohl, W. König, J. Knolle and B. A. Schölkens (1991). Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br. J. Pharmacol. 102, 769-773.
41. 8] bradykinin. Biochemistry 33, 2373-2379.
42. M. L. Hoefle and G. Bobowski (1982). Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acid. US Patent 4,350,704 (Cl.424-274; A61K31/405).
43. M. Vincent, G. Remond, B. Portevin, B. Serkiz and M. Laubie (1982). Stereoselective synthesis of new perhydroindole derivative of chiral iminodiacid, a potent inhibitor of angiotensin converting enzyme. Tetrahedron Lett. 23, 1677-1680.
44. C. J. Blankley, J. S. Kaltenbronn, D. E. DeJohn, A. Werner, L. R. Bennett, G. Bobowski, U. Krolls, D. R. Johnson, W. M. Pearlman, M. L. Hoefle, A. D. Essenburg, D. M. Cohen and H. R. Kaplan (1987). Synthesis and structure-activity relationships of potent new angiotensin converting enzyme inhibitors containing saturated bicyclic amino acids. J. Med. Chem. 30, 992-998.
45. T. Sawayama, M. Tsukamoto, T. Sasagawa, K. Nishimura, R. Yamamoto, T. Deguchi, K. Takeyama and K. Hosoki (1989). Angiotensin-converting enzyme inhibitors: Synthesis and structure-activity relationships of potent N-benzyloxycarbonyl tripeptide inhibitors. Chem. Pharm. Bull. 37, 2417-2422.
46. A. Grouiller, J. -Y. Nioche, J. Baraller, M. Roche and H. Pacheco (1980). Analogues et derives de la p. chlorophenylalanine: Synthese, properties biochemiques et pharmacologiques. Eur. J. Med. Chem. Chim Ther., 15, 139-146.
47. D. T. Vistica, R. Fuller, N. Dillon and B. J. Petro (1983). Comparative reactivity of cyclic amino acids with systhem L in murine L1210 leukemia cells and murine bone marrow progenitor cells (CFU-C): a potential basis for selective drug design. UCLA Symp. Mol. Cell. Biol., New Ser. 4 (Rational Basis Chemother.), 475-485.
48. G. Toth, M. Lebl and V. Hruby (1990). Chiral thin-layer chromatographic separation of phenylalanine and tyrosine derivatives. J. Chromatogr. 504, 450-455.
49. T. Deeks, P. A. Crooks and R. D. Walgh (1984). Leucine enkephalin analogues containing a conformationally restrained N-terminal amino acid residue. J. Pharm. Sci. 73, 457-460.
50. P. W. Schiller, G. Weltrowska, T. M.-D. Nguyen, C. Lemieux, N. N. Chung, B. J. Marsden and B. C. Wilkes (1991). Conformational restriction of the phenylalanine residue in a cyclic oploid peptide analogue: effects on receptor selectivity and stereospecificity. J. Med. Chem. 34, 3125-3132.
51. P. E. Gagnon and J. L. Bolvin (1948). Synthesis of amino acids from substituted cyanoacetic esters. Can. J. Research B26, 503-510.
52. R. M. Pinder, B. H. Butcher, D. A. Buxton and D. J. Howells (1971). 2-aminoindan-2-carboxylic acids. Potential tyrosine hydrolase inhibitors. J. Med. Chem. 14, 892-893.
53. J. G. Cannon, J. P. O'Donnell, J. P. Rosazza and C. R. Hoppin (1974). Rigid amino acids related to α-methyldopa. J. Med. Chem. 17, 565-568.
54. K. H. Ksieh and E. C. Jorgensen (1979). Angiotensin II analogues. 12. Role of the aromatic ring of position 8 phenylalanine in pressor activity. J. Med. Chem. 22, 1038-1044.
55. K. H. Hsieh, T. R. LaHann and R. C. Speth (1989). Topographic probes of angiotensin and receptor: Potent angiotensin II agonist containing diphenylalanine and long-acting antagonists containing biphenylalanine and 2-indan amino acid in position 8. J. Med. Chem. 32, 898-903.
56. 6 interchange in non-selective and selective vasopressin and oxytocin antagonists. J. Med. Chem. 38, 1762-1769.
57. R. B. Merrifield (1963). Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85, 2149-2154.
58. R. B. Merrifield (1964). Solid-phase peptide synthesis. III. An improved synthesis of bradykinin. Biochemistry 3, 1385-1390.
59. J. M. Stewart and J. D. Young: Solid Phase Peptide Synthesis, Pierce Chemical Company, Rockford 1984.
60. M. Manning (1968). Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin. J. Am. Chem. Soc. 90, 1348-1349.
61. W. A. Klis, L. L. Cheng, S. Stoev, N. C. Wo, W. Y. Chan and M. Manning In: Peptides. P. Kaumaya and R. S. Hodges, Eds., p. 372-373, Mayflower Scientific Ltd., 1996.
62. W. Koenig and R. Geiger (1970). New method for the synthesis of peptides: Activation of the carboxyl group with dicyclohexylcarbodiimide by using 1-hydroxybenzotriazole as additives. Chem. Ber. 103, 788-798.
63. M. Bodanszky and V. du Vigneaud (1959). A method of synthesis of long peptide chains using a synthesis of oxytocin as an example. J. Am. Chem. Soc. 81, 5688-5691.
64. M. Bodansky and J. T. Sheehan (1964). Active esters and resins in peptide synthesis. Chem. Ind. 1423-1424.
65. V. du Vigneaud, C. Ressler, J. M. Swan, C. W. Roberts and P. G. Katsoyannis (1954). The synthesis of oxytocin. J. Am. Chem. Soc. 76, 3115-3121.
66. D. V. Hope, V. V. S. Murti and V. du Vigneaud (1962). A highly potent analogue of oxytocin, desamino-oxytocin. J. Biol. Chem. 237, 1563-1566.
67. J. Rivier, R. Kaiser and R. Galyean (1978). Solid-phase synthesis of somatostatin and glucagon-selective analogs in gram quantities. Biopolymers 17, 1927-1938.
68. M. Manning, T. C. Wuu and J. W. M. Baxter (1968). The purification of synthetic oxytocin and analogues by gel filtration on Sephadex G-15. J. Chromatogr. 38, 396-398.
69. P. Holton (1948). A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br. J. Pharmacol. 3, 328-334.
70. H. O. Schild (1947). PA, a new scale of the measurement of drug antagonism. Br. J. Pharmacol. Chemother. 2, 189-206.
71. D. F. Dykes, J. J. Nestor Jr. M. F. Ferger and V. du Vigneaud (1974). [1-β-Mercapto-β,β-diethylpropionic acid]-8-lysine-vasopressin, a potent inhibitor of 8-lysine-vasopressin and of oxytocin. J. Med. Chem. 17, 250-252.
72. W. H. Sawyer (1958). Differences in antidiuretic responses of rats to the intravenous administration of lysine and arginine vasopressins. Endocrinology 63, 694-698.
73. J. Dekanski (1952). The quantitative assay of vasopressin. Br. J. Pharmacol. 7, 567-572.
74. R. A. Munsick (1960). Effect of magnesium ion on the response of the rat uterus to neurohypophysical hormones and analogues. Endocrinology 66, 451-457.
75. F. C. Bartter and W. B. Schwartz (1967). The syndrome of inappropriate secretion of antidiuretic hormone. Am. J. Med. 42, 760-806.
76. J. J. Nestor, Jr., M. F. Ferger and V. du Vigneaud (1975). [1-β-Mercapto-β,β-pentamethylenepropionic acid] oxytocin, a potent inhibitor of oxytocin. J. Med. Chem. 18, 284-287.
77. B. F. Gisin (1973). The preparation of Merrifield-resin through total esterification with cesium salts. Helv. Chim. Acta 56, 1476-1482.